P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2021-10, Vol.16 (10), p.S1059-S1060
Hauptverfasser:	Douglas, C., Lord, H.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	S1060
container_issue	10
container_start_page	S1059
container_title	Journal of thoracic oncology
container_volume	16
creator	Douglas, C. Lord, H.
description
doi_str_mv	10.1016/j.jtho.2021.08.418
format	Article
fullrecord	<record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8523141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086421028410</els_id><sourcerecordid>S1556086421028410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1958-2bd01f82ada16eb0220421ba2a5a7f8c05b82dd00d7ecfab08c5320adcce79dd3</originalsourceid><addsrcrecordid>eNp9kMtKw0AUhoMoWKsv4GpeIPHMJJNOQQSpt0KhXVS7HOZyYifmUiaxWFe-g2_ok5jSKrhxdW58P5wvCM4pRBRoepFHebusIwaMRiCihIqDoEc5T0MaCzjc9yDS5Dg4aZocIOGQiF6wmMVJBJSk4QLxpdiQdUPin36GpfZ14d5fS6XJ18cnmddvzrjWYUNUZbuxQK8qg8RVZL5EMpo-jW_CbncaHGWqaPBsX_vB493tfPQQTqb349H1JDR0yEXItAWaCaasoilqYAwSRrViiqtBJgxwLZi1AHaAJlMahOExA2WNwcHQ2rgfXO1yV6-6RGuwar0q5Mq7UvmNrJWTfy-VW8rnei0FZzFNaBfAdgHG103jMftlKcitW5nLrVu5dStByM5tB13uIOxeWzv0sjEOOw_WeTSttLX7D_8GdJOEIw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Douglas, C. ; Lord, H.</creator><creatorcontrib>Douglas, C. ; Lord, H.</creatorcontrib><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1016/j.jtho.2021.08.418</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1059-S1060</ispartof><rights>2021</rights><rights>Copyright © 2021 Published by Elsevier Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Douglas, C.</creatorcontrib><creatorcontrib>Lord, H.</creatorcontrib><title>P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era</title><title>Journal of thoracic oncology</title><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKw0AUhoMoWKsv4GpeIPHMJJNOQQSpt0KhXVS7HOZyYifmUiaxWFe-g2_ok5jSKrhxdW58P5wvCM4pRBRoepFHebusIwaMRiCihIqDoEc5T0MaCzjc9yDS5Dg4aZocIOGQiF6wmMVJBJSk4QLxpdiQdUPin36GpfZ14d5fS6XJ18cnmddvzrjWYUNUZbuxQK8qg8RVZL5EMpo-jW_CbncaHGWqaPBsX_vB493tfPQQTqb349H1JDR0yEXItAWaCaasoilqYAwSRrViiqtBJgxwLZi1AHaAJlMahOExA2WNwcHQ2rgfXO1yV6-6RGuwar0q5Mq7UvmNrJWTfy-VW8rnei0FZzFNaBfAdgHG103jMftlKcitW5nLrVu5dStByM5tB13uIOxeWzv0sjEOOw_WeTSttLX7D_8GdJOEIw</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Douglas, C.</creator><creator>Lord, H.</creator><general>Elsevier Inc</general><general>Published by Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202110</creationdate><title>P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era</title><author>Douglas, C. ; Lord, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1958-2bd01f82ada16eb0220421ba2a5a7f8c05b82dd00d7ecfab08c5320adcce79dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Douglas, C.</creatorcontrib><creatorcontrib>Lord, H.</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Douglas, C.</au><au>Lord, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era</atitle><jtitle>Journal of thoracic oncology</jtitle><date>2021-10</date><risdate>2021</risdate><volume>16</volume><issue>10</issue><spage>S1059</spage><epage>S1060</epage><pages>S1059-S1060</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><pub>Elsevier Inc</pub><doi>10.1016/j.jtho.2021.08.418</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1556-0864
ispartof	Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1059-S1060
issn	1556-0864 1556-1380
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8523141
source	EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title	P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P34.01%206-Weekly%20vs%203-Weekly%20Pembrolizumab%20%E2%80%93%20Toxicities%20and%20Tolerance%20in%20The%20COVID-era&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Douglas,%20C.&rft.date=2021-10&rft.volume=16&rft.issue=10&rft.spage=S1059&rft.epage=S1060&rft.pages=S1059-S1060&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1016/j.jtho.2021.08.418&rft_dat=%3Celsevier_pubme%3ES1556086421028410%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S1556086421028410&rfr_iscdi=true